Farallon Capital Management Llc increased Chemocentryx Inc (CCXI) stake by 21.05% reported in 2018Q2 SEC filing. Farallon Capital Management Llc acquired 200,000 shares as Chemocentryx Inc (CCXI)’s stock declined 9.17%. The Farallon Capital Management Llc holds 1.15 million shares with $15.15 million value, up from 950,000 last quarter. Chemocentryx Inc now has $465.34 million valuation. The stock decreased 2.54% or $0.24 during the last trading session, reaching $9.21. About 51,462 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 51.30% since November 20, 2017 and is uptrending. It has outperformed by 35.68% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA
The stock increased 1.02% or $0.19 during the last trading session, reaching $19.09. About 159,335 shares traded. PGT Innovations, Inc. (NYSE:PGTI) has risen 75.36% since November 20, 2017 and is uptrending. It has outperformed by 59.74% the S&P500. Some Historical PGTI News: 04/05/2018 – PGT Closes Above 50-Day Moving Average: Technicals; 19/04/2018 – TEVA PHARMACEUTICAL – WILL MERGE ITS OTC INTERESTS RETURNING FROM PGT WITH A PORTFOLIO OF OTC ASSETS ACQUIRED IN 2016 VIA ACTAVIS ACQUISITION; 01/05/2018 – PGT Innovations 1Q EPS 14c; 13/04/2018 – PETROBRAS: PGT SIGNED UP TO $400M LOAN WITH CACIB; 19/04/2018 – Teva and the Procter & Gamble Co Have Agreed to Terminate the PGT Healthcare Partnership; 16/03/2018 – PGT Innovations Celebrates Female Leadership During Women’s History Month; 19/04/2018 – TEVA & PROCTER & GAMBLE CO. HAVE AGREED TO TERMINATE PGT; 19/04/2018 – TEVA & PROCTER HAVE AGREED TO TERMINATE PGT HEALTHCARE PACT; 19/04/2018 – Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership; 24/05/2018 – Consolidated Research: 2018 Summary Expectations for PGT, National Commerce, CrossAmerica Partners LP, Destination XL Group, Al
Since May 25, 2018, it had 0 insider buys, and 3 selling transactions for $2.73 million activity. The insider Hershberger Rodney sold 45,400 shares worth $924,344. Another trade for 5,010 shares valued at $105,461 was sold by Feintuch Richard D. 83,601 shares were sold by MCHUGH M JOSEPH, worth $1.70 million on Friday, May 25.
Investors sentiment increased to 1.67 in 2018 Q2. Its up 0.36, from 1.31 in 2018Q1. It improved, as 9 investors sold PGT Innovations, Inc. shares while 45 reduced holdings. 31 funds opened positions while 59 raised stakes. 43.08 million shares or 0.54% less from 43.32 million shares in 2018Q1 were reported. Gotham Asset Mngmt Limited Liability has 10,988 shares. 16,312 are held by Teachers Retirement System Of The State Of Kentucky. Rice Hall James & Associates Ltd Company, a California-based fund reported 41,619 shares. 52,754 were accumulated by Comerica Bancshares. Dubuque Fincl Bank And accumulated 390 shares. 839 were accumulated by Meeder Asset Mgmt. Tiaa Cref Ltd Llc has invested 0.01% in PGT Innovations, Inc. (NYSE:PGTI). 33,160 were accumulated by Barclays Plc. Ardsley Advisory Prtnrs stated it has 0.05% in PGT Innovations, Inc. (NYSE:PGTI). Jennison Assoc Ltd Liability has invested 0.03% of its portfolio in PGT Innovations, Inc. (NYSE:PGTI). 39,259 were accumulated by Peak6 Investments L P. Hsbc Plc has invested 0.02% in PGT Innovations, Inc. (NYSE:PGTI). D E Shaw & Company Incorporated owns 0% invested in PGT Innovations, Inc. (NYSE:PGTI) for 16,960 shares. The New York-based Lazard Asset Management Ltd has invested 0.06% in PGT Innovations, Inc. (NYSE:PGTI). Bancshares Of Montreal Can invested in 67,335 shares or 0% of the stock.
PGT Innovations, Inc. manufactures and supplies residential impact-resistant windows and doors in the Southeastern United States, the Gulf Coast, Coastal mid-Atlantic, the Caribbean, Central America, and Canada. The company has market cap of $1.11 billion. The firm offers heavy-duty aluminum or vinyl frames with laminated glass to provide protection from hurricane-force winds and wind-borne debris; and non-impact vinyl windows with insulating glass and multi-chambered frames for various climate zones. It has a 15.68 P/E ratio. It also provides customizable non-impact-resistant aluminum frame windows and doors; and non-glass vertical and horizontal sliding panels for porch enclosures, including vinyl-glazed aluminum-framed products used for enclosing screened-in porches that provide protection from inclement weather, as well as cabana doors.
Yesterday, an insider trading trade was made. Richard Feintuch, the director and an insider of Pgt Innovations Inc sold a total of 5,010 shares of Pgt Innovations Inc, worth about $105,461 U.S Dollars, at $21.1 a share at the time of the trade. This trade decreased his ownership of the Company to 0.17% market cap or 96,800 shares. Richard reported this deal on 13-11-2018. The report is accessible online here at the (SEC) website.
Another recent and important PGT Innovations, Inc. (NYSE:PGTI) news was published by Seekingalpha.com which published an article titled: “PGT Innovations, Inc. (PGTI) CEO Jeffrey Jackson on Q3 2018 Results – Earnings Call Transcript” on November 04, 2018.
More recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights” on November 08, 2018. Also Seekingalpha.com published the news titled: “ChemoCentryx (CCXI) CEO Thomas Schall on Q3 2018 Results – Earnings Call Transcript” on November 09, 2018. Seekingalpha.com‘s news article titled: “ChemoCentryx 2018 Q3 – Results – Earnings Call Slides” with publication date: November 08, 2018 was also an interesting one.
Since May 21, 2018, it had 0 buys, and 7 sales for $88.11 million activity. $1.34M worth of stock was sold by KANAYA SUSAN M on Tuesday, June 26. On Friday, October 26 Cappel Markus J. sold $332,779 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 30,237 shares. Schall Thomas J. had sold 7,211 shares worth $86,554 on Wednesday, November 7. GLAXOSMITHKLINE PLC sold $85.85M worth of stock.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. ChemoCentryx had 4 analyst reports since June 28, 2018 according to SRatingsIntel. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Monday, November 12 by Canaccord Genuity. The firm has “Neutral” rating given on Tuesday, August 14 by JP Morgan.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.